Ideaya Biosciences Inc. has announced the selection of a Werner helicase inhibitor development candidate. The candidate is a potent, selective, small-molecule inhibitor of the helicase domain of Werner protein and is being advanced for tumors characterized by high microsatellite instability (MSI-high).
Recurrent driver mutations in FMS-related receptor tyrosine kinase 3 (FLT3) occur in around one-third of patients with de novo acute myeloid leukemia (AML). Although most FLT3 mutations are secondary events in leukemogenesis, they are associated with accelerated clonal expansion and disease progression, and treatment with the tyrosine kinase inhibitor midostaurin has been shown to increase patients’ long-term survival. However, the efficacy of FLT3 inhibitors in eliminating FLT3-mutated clones is variable.
Just as Wall Street had begun mulling the possible fallout of the regulatory vote against full U.S. FDA clearance for Amgen Inc.’s KRAS G12C therapy for non-small-cell lung cancer, a new – albeit not entirely unexpected – development cropped up in the space. Mirati Therapeutics Inc. disclosed Oct. 9 that Bristol Myers Squibb Co. (BMS) is offering to take over the firm in a deal that could be worth as much as $5.8 billion, historically one of the larger takeovers for 2023.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. scientists have developed kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Histone deacetylase 8 (HDAC8) inhibitors have been reported in a Sookmyung Women’s University patent as potentially useful for the treatment of cancer, neurodegeneration, autoimmune disease, fibrosis and inflammatory disorders.
Finding suitable antigens for immunotherapy of myeloid malignancies, particularly acute myeloid leukemia (AML), is an urgent clinical need. Most AML candidate targets, including CD123, are co-expressed by hematopoietic stem and progenitor cells (HSCPs), with the subsequent risk of myelosuppression associated with myeloid cell-targeted chimeric antigen receptor (CAR) T therapy.
Radiopharm Theranostics Ltd. has been granted human research ethics committee (HREC) approval to commence a first-in-human phase I study in Australia for RAD-204, the company’s radiotherapeutic for patients with PD-L1-positive non-small-cell lung cancer (NSCLC).
The structures of the majority of PD-1/PD-L1 inhibitors currently in use are derived from the arylmethylamine/biphenyl scaffold. Researchers from Southern Medical University reported on the discovery and preclinical evaluation of a novel series of non-arylmethylamine-based PD-1/PD-L1 inhibitors for use in cancer immunotherapy.
Guangzhou Maxinovel Pharmaceuticals Co. Ltd. has described thienopyrimidine compounds acting as ALK, fibroblast growth factor receptor (FGFR) and high affinity nerve growth factor (TRK) inhibitors reported to be useful for the treatment of cancer, infections and psoriasis and inflammation.
Nammi Therapeutics Inc. has divulged prodrugs of Toll-like receptor (TLR) agonists and its self-assembled lipid nanoparticles reported to be useful for the treatment of cancer and immunological disorders.
RSS
